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Abstract 
Aims 
As of the 28th April 2020, the COVID-19 pandemic has infiltrated over 200 countries 
and affected over three million confirmed people. We review different biomarkers to 
evaluate if they are able to predict clinical outcomes and correlate with the severity of 
COVID-19 disease.  
Methods 
A systematic review of the literature was carried out to identify relevant articles using 
six different databases. Keywords to refine the search included ‘COVID-19’, ‘SARS-
CoV2’, ‘Biomarkers’, among others. Only studies which reported data on pre-defined 
outcomes were included. 
Key Findings 
Thirty-four relevant articles were identified which reviewed the following biomarkers: 
C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, 
neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, renal biomarkers, 
lymphocytes and platelet count. Of these, all but two, showed significantly higher 
levels in patients with severe complications of COVID-19 infection compared to their 
non-severe counterparts. Lymphocytes and platelet count showed significantly lower 
levels in severe patients compared to non-severe patients.  
Significance 
Although research is still in its early stages, the discovery of how different 
biomarkers behave during the course of the disease could help clinicians in 
identifying severe disease earlier and subsequently improve prognosis. 
Nevertheless, we urge for more research across the globe to corroborate these 
findings. 
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Introduction 
 
On December 2019, Wuhan City in China, became the epicentre of unexplained 
cases of pneumonia. On January 2020, Chinese scientists identified this as a novel 
coronavirus, temporarily labelled as, severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2)(1). Its name was then changed to coronavirus disease 2019 
(COVID-19) by the World Health Organization in February 2020 as the disease 
spread worldwide (2). 
It has been suggested the outbreak has a zoonotic origin, and like other respiratory 
pathogens, it spreads through human-to-human transmission such as coughing and 
sneezing(3). Although limited, research suggests a possibility of transmission even 
amongst the asymptomatic(4). 
As of the 28th April 2020, over 200 countries have been affected by the COVID-19 
disease with over three million confirmed cases leading to over 200,000 deaths. Yet 
it is believed many remain unreported in certain areas of the world(1). 
Infected patients may present with any of the following; fever, high temperature 
(>37.3 C), cough, myalgia, sputum production, headache, haemoptysis, diarrhoea, 
dyspnoea and in some cases, acute respiratory distress syndrome (ARDS), acute 
cardiac injury or secondary infection(5).  
Upon examination, these subjective clinical symptoms can be interpreted more 
confidently with the use of biological markers (biomarkers). These provide objective 
values throughout the progression of the disease(6). Henceforth, categorising 
patients into mild, severe or critical becomes more defined, allowing for earlier 
interventions (7). 
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This article aims to explore the role of different biomarkers in the disease 
pathogenesis of COVID-19 and assess how their levels vary depending on the 
severity of the disease. By doing so, it gives clinicians a tool to group patients and 
predict prognosis and mortality. The biomarkers we review include, C-reactive 
protein (CRP), IL-6, white cell count (WCC), lactate dehydrogenase (LDH), D-
dimers, platelet count, cardiac troponin and renal markers. 
 
Methods and Materials 
1. Search Strategy 
A comprehensive literature search was done on PubMed, SCOPUS, Embase, 
Cochrane database, Google Scholar and Ovid to identify articles discussing 
biomarkers in this review and its clinical implications on COVID-19 in accordance 
with Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
guidelines. Key words used were ‘C-reactive protein’ ‘COVID-19’, ‘interleukin-6’, 
‘lactate dehydrogenase’, ‘SARS’, ‘white cell count’, ‘neutrophil count’, ‘lymphocyte 
count’, ‘D-dimer’, ‘platelet count’, ‘cardiac troponin’, ‘renal biomarkers’, ‘urea’ 
‘creatinine’. The search terms were used as key words and in combination as MeSH 
terms to maximize the output from literature findings. A staged literature search was 
done, whereby a separate literature search was performed for each section within 
this article and all the relevant studies were identified and summarized separately. If 
a paper reports on multiple biomarker, then the results have been shared between 
different parts of this review. The relevant articles are cited and referenced within 
each section separately. No limit has been placed on publication time or language of 
the article. All the relevant articles were identified and screened by three authors; the 
results are summarized in narrative manner in each relevant section of this review. A 
summary table of each section is provided where appropriate. 
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2. Inclusion and exclusion criteria: 
Studies were included if they have reviewed a correlation between a biomarker and 
the severity of COVID-19. Exclusion criteria were editorials, consensus documents, 
commentaries, and studies with no particular definition of the role of biomarkers in 
COVID-19.  
3. Data extraction:  
All articles were screened by two authors and any disagreement was reached by 
consensus or involvement of third author. Data extracted by two authors and 
validated by third author.  
4. Quality assessment:  
Quality of each publication was evaluated by two independent reviewers. This review 
addressed key domains: type of biomarker, level of the biomarker, correlation with 
severity of the disease, survival, number of patients investigated and outcomes.  
5. Statistical analysis:  
It was not possible to conduct an appropriate meta-analysis because there were not 
enough research data among the studies on this subject. 
 
Results 
A total of 414 articles were found. After removal of duplicates, 224 articles were used 
for full-text screening with 34 studies included in our analysis. The complete PRISMA 
flow chart is reported in figure 1. Biomarkers measured were C-reactive protein 
(CRP), interleukin-6 (IL-6), White cell count (WCC), lactate dehydrogenase (LDH), 
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D-dimer, platelet count, high-sensitivity troponin I (hs-TnI) and renal markers. Table 
1 summarises the study’s characteristics.  
 
C-reactive protein 
CRP is a plasma protein produced by the liver and induced by various inflammatory 
mediators such as IL-6. Despite being non-specific, this acute phase reactant is used 
clinically as a biomarker for various inflammatory conditions; a rise in CRP levels are 
associated with an increase in disease severity(7). 
The application of CRP in COVID-19 has been highlighted by a retrospective single-
centre study in Wuhan, China, where the majority of patients in the severe cohort 
showed significantly higher levels compared to the non-severe cohort (57.9 mg/L vs 
33.2 mg/L, P < 0.001)(8). A second retrospective cohort study found the likelihood of 
progressing to severe COVID-19 disease increased in patients with CRP levels 
greater than 41.8mg/L(9). Both studies suggest CRP levels are a strong indicator to 
reflect the presence and severity of COVID-19 infection. 
Furthermore, a study from unpublished observations suggests CRP is one of the first 
biomarkers within blood plasma that changes to reflect physiological complications; if 
accepted CRP will be the most effective biomarker to predict the progression of 
COVID-19 infection. Contrastingly, the same study illustrated some cases of 
infection which showed changes in serum amyloid A (SAA) instead of evoking 
significant CRP changes thus requiring further evaluation (10).  
Whilst the use of SAA as a biomarker for COVID-19 requires further research, CRP 
and SAA are commonly used in conjunction to monitor inflammatory diseases. 
Though SAA is another acute phase reactant, it is responsive to both viral and 
bacterial infections compared to CRP(11).  
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Pathologically, computed tomography (CT) scans can identify lung lesions relating to 
COVID-19. Nonetheless, a study conducted in China revealed CT scores could not 
differentiate mild cases from severe. However, compared to erythrocyte 
sedimentation rate (ESR), CRP levels were significantly greater during early periods 
of severe cases and proved to be a more sensitive biomarker in reflecting disease 
development(12).   
The excellent performance of CRP as a biomarker is reflected in the ‘area under 
curve’ in the receiver operating analysis of 0.87 (95% CI, 0.10–1.00) where values 
83% and 91% represent sensitivity and specificity, respectively. Hence compared to 
CT scans alone, CRP values are more reliable for earlier identification of case 
severity (12). Table 2 summarises the studies used in analysing CRP and COVID-
19. 
 
Interleukin-6 
Cytokine release syndrome (CRS) is an over-exaggerated immune response 
involving an overwhelming release of pro-inflammatory mediators. This mechanism 
underlies several pathological processes including acute respiratory distress 
syndrome (ARDS) (13). Studies investigating the role of cytokines in SARS and 
MERS have had also found a link between CRS and disease severity(14). 
Understanding their role in COVID-19 disease may help facilitate the design of novel 
immunotherapies. 
Studies have revealed that levels of IL-6, the most common type of cytokine 
released by activated macrophages, rise sharply in severe manifestations of COVID-
19(15). However, since most studies to date have been observational, it is difficult to 
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extrapolate if the rise is significant enough to cause the manifestations seen in 
severe forms. 
One meta-analysis reviewing six studies show mean IL-6 concentrations were 2.9-
fold higher in patients with complicated COVID-19 compared to those with non-
complicated disease (n=1302; 95% CI 1.17-7.19)(16). In its analysis, the outcomes 
of the studies include ICU admission, onset of ARDS and mortality. Since the 
proportionate rise of IL-6 is correlated with disease severity, this study can prove 
ground-breaking. Although clinicians can use this to identify severity earlier and 
commence oxygen therapy sooner, the varying outcomes makes it somewhat 
difficult to ascertain what level of IL-6 corresponds to what negative outcome. 
Furthermore, many studies recruited participants from the same centre, giving rise to 
the potential of selection bias. Table 3 summarises the studies used in analysing IL-6 
and COVID-19. 
 
White Cell Count 
White blood cells (WBCs), known as leucocytes are a component of blood generated 
from bone marrow and lymphoid tissue. They are divided into two major groups, 
granulocytes and agranulocytes. Within the granulocyte group are eosinophils, 
basophils and neutrophils (NC), whereas lymphocytes (LC) and monocytes are 
present in agranulocytes. A disproportionate number of these cells may reveal an 
underlying infection and hence can be measured using blood tests, producing a 
WCC.  However, the reliability of WCC as a biomarker for COVID-19 remains 
unproven. 
A retrospective study found several differences in WCC between severe and non-
severe COVID-19 patients(8). Both groups experienced an increase in leucocytes 
with the severe group having a significantly greater rise (5.6 vs 4.9 × 109/L ; P < 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 9 
0.001). NCs were predominantly driving this increase as the severe set (4.3 vs 3.2 × 
109/L ; P < 0.001). Interestingly, the levels of lymphocytes, monocytes, basophils and 
eosinophils were less, resulting in a greater neutrophil-to-lymphocyte ratio (NLR; 5.5 
vs 3.2; P < 0.001). NLR is an infamous biomarker, high in wide-spread inflammatory 
conditions and can be used to reflect disease severity. However, a larger study is 
needed to clarify NLR’s effectiveness as a biomarker.  
Another conducted in China concludes similar findings of high NC and low LC count 
in severely affected patients, suggesting NLR could be a potential biomarker for 
early detection of severe COVID-19 (17).  
 However, other factors may disrupt the accuracy of the WCC results observed. 
These include glucocorticoid therapy and other underlying viral/bacterial 
infections(11).  
LC is separately addressed in the literature, secondary to NLR. A descriptive study in 
China reported depleted LC levels in the majority of COVID-19 patients(15). 
Another study has found low blood lymphocyte percentage (LYM%) in critically ill 
patients, suggesting low LC count indicates poor prognosis. However, since the virus 
can target lymphoid tissue and mechanisms of IL-6, other causes of low LC count 
must be investigated(18). Similar to NLR, the clinical benefits of LC count as a 
biomarker for COVID-19 remains uncertain. 
Table 4 summarises the studies used in analysing WCC and COVID-19. 
 
Lactate Dehydrogenase 
In glucose metabolism, the enzyme LDH converts pyruvate to lactate. LDH secretion 
is triggered by necrosis of the cell membrane, hinting to viral infection or lung 
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damage, such as the pneumonia induced by SARS-CoV-2 (19). There is convincing 
evidence linking LDH levels to the development of COVID-19 disease (20).  
A study found significantly higher levels of LDH in ICU patients than non-ICU 
patients (248 U/L vs 151 U/L, p=0.002). Since high levels of LDH continued in the 
ICU patients number of days post-admission (160 U/L vs 218 U/L, p=0.002), LDH 
may be a predictive biomarker of severe disease. However, the one centre study 
may be prone to selection bias which could potentially reduce its validity (21). 
A multi-centre study involving 1099 patients reported supporting evidence correlating 
extent of tissue damage and inflammation with increasing levels of LDH(22). 
Furthermore, when LDH levels were correlated with CT scans, significantly higher 
levels reflected the severity of pneumonia(23).  
There is increasing confidence in using LDH as a biomarker to measure severity of 
COVID-19 infection. Another study found that there was a significant rise in LDH 
levels among refractory COVID-19 patients (24). 
Table 5 summarises the studies used in analysing LDH and COVID-19. 
 
D-dimer 
D-dimer originate from the lysis of cross-linked fibrin with rising levels indicating the 
activation of coagulation and fibrinolysis(25). Early studies have associated COVID-
19 with haemostatic abnormalities with one study observing elevated levels of D-
dimer, the measure of coagulation, in non-survivors compared to survivors(26).  
A retrospective cohort study composed of 191 patients found that D-dimer levels 
greater than 1.0 µg/ml (p=0.0033) were associated with increased mortality among 
COVID-19 patients. Furthermore, they found that levels of 2.0 µg/ml or more on 
admission was the optimum cut-off to predict in-hospital mortality for COVID-19(27). 
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Studies have reported that nearly 90% of inpatients with pneumonia had increased 
coagulation activity marked rising D-dimer levels(28).  
Furthermore, Huang et al. found that levels of D-dimer on admission could be used 
to triage patients into critical care (5). The researchers found that median D-dimer 
levels were higher in ICU patients compared to non-ICU patients (2.4 mg/L vs. 
0.5mg/L; p=0.0042). This, along with the previous study, suggest that D-dimer levels 
can be used as a prognostic marker and help clinicians monitor those who are likely 
to deteriorate earlier. However, this study confirmed the diagnosis of COVID-19 
using lower respiratory tract specimens and did not use paired nasopharyngeal 
swabs to investigate the viral RNA detection rate between the upper and lower 
respiratory tract specimens. Secondly, with a cohort size of 41 patients, it is difficult 
to assess predictors of disease severity and mortality with multivariable-adjusted 
methods. 
Table 6 summarises the studies used to analyse D-dimer and COVID-19. 
 
Platelet count 
As seen with previous coronavirus outbreaks, COVID-19 infection leads to severe 
haematological changes leading to thrombocytopenia. 
Meta-analysis of 1799 patients reveal those with severe COVID-19 infections had 
significantly lower platelet counts (WMD −31 × 109/L; 95% CI, −35 to −29 × 
109/L)(29). When using mortality as an endpoint, non-survivors evidently had a 
significantly lower platelet count (WMD, −48 × 109/L; 95% CI, −57 to −39 × 109/L). 
Using thrombocytopenia as an endpoint also revealed a fivefold greater risk of 
COVID-19 (OR, 5.13; 95% CI, 1.81-14.58). Despite the varying definitions of disease 
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severity and thrombocytopenia having an influence on results analysis, platelet count 
could possibly be used clinically to indicate infection severity.  
A retrospective study which used Cox proportional hazard regression analysis found 
that platelet count is an independent risk factor for mortality among COVID-19  
patients, where a 50x109/L increase is associated with 40% deceased mortality (HR 
0.60, 95%CI: 0.43, 0.84)(30). Here, thrombocytopenia at admission was more likely 
to occur in non-survivors than in survivors. Although many risk factors were 
accounted for in this study, the possibility for unmeasured confounder cannot be 
excluded. 
Another study corroborates the previously documented work. The nadir platelet 
count was significantly associated with mortality – and the lower the nadir, the 
stronger the association(31). Again, thrombocytopenia was more likely to occur in 
non-survivors than survivors. This study is from adequate sample sizes providing 
statistical power, however, similar to the previous studies, they are all retrospective 
making the correlation seen difficult to extrapolate from. 
Testing the platelet count is a routine part of laboratory tests and the literature 
suggests it has inherent value in providing more detail on the patient’s condition.  
Table 7 summarises the studies used in analysing platelet count and COVID-19. 
 
Cardiac Troponin 
There is growing evidence of higher mortality rates among those with underlying 
cardiovascular disease due to COVID-19 infection (22). Some have investigated the 
use of high-sensitivity cardiac troponin I (hs-TnI) as a marker of disease progression 
and mortality.  
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A retrospective study performed in China of patients with confirmed COVID-19 
based on SARS-CoV-2 RNA detection, revealed a univariable odds ratio for death at 
80.1 (95% CI 10.3-620.4, p<0.0001) for hs-TnI(32). This risk was higher compared to 
other biomarkers such as D-dimer and lymphocyte count. Another study of 416 
hospitalised patients with COVID-19 reported that hs-TnI was elevated in 1 in 5 
patients on presentation(33). These patients were more likely to require invasive 
(22% vs 4%, p<0.001) or non-invasive (46% vs 4% , p<0.001) ventilation, develop 
ARDS (59% vs 15%, p<0.001) or acute kidney injury (9% vs 0%, p<0.001).   
Early recognition of myocardial injury indicated by elevated hs-TnI aid in appropriate 
triage to a critical care area and inform the use of inotropes and vasopressors. 
However, elevated levels are common in hospitalized patients and are likely to be 
due to non-ischaemic causes of myocardial injury. This may lead to inappropriate 
use of cardiology consultation and downstream testing and increased risk to cardiac 
physiology staff.  
Table 8 summarises the studies used in analysing hs-TnI and COVID-19. 
 
Renal markers 
There is also evidence that chronic kidney disease is associated with severe forms 
of COVID-19 infection(34).  
Studies have demonstrated significantly higher levels of renal biomarkers such as 
serum urea, creatinine and markers of glomerular filtration rate in severe cases(35). 
Since these results stem from the analysis of 28 patients, extrapolation across larger 
cohorts is more difficult. 
A larger study of 701 patients revealed that elevated serum creatinine levels on 
admission correlated with severity due to significant abnormalities in the coagulation 
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pathway(36). They also found that these patients were more likely to require 
mechanical ventilation or be placed in intensive care. Univariate Cox regression 
analysis found elevated creatinine levels was also associated with in-hospital 
mortality (HR 2.99, 95% CI: 2.00, 4.47). Proteinuria, haematuria and elevated urea 
levels had similar, if not larger, hazard ratios.  
Interestingly, another study showed a potential role for urinalysis over serum 
markers of kidney function(37). Here, abnormalities in the routine urine test on 
admission correlated strongly with disease severity. They go on to suggest that 
urinalysis may reveal kidney impairment more readily than evaluation of serum renal 
biomarkers. However, these tests were only carried out on admission and so 
patients in earlier stages of the infection had changes in serum levels obscured by 
compensatory kidney function. Hence renal abnormalities on admission may indicate 
higher risks of deterioration, ensuring appropriate triaging. 
Table 9 summarises the studies used in analysing renal markers and COVID-19. 
 
Discussion 
COVID-19 is a rapidly spreading pandemic increasing the burden on medical 
facilities. Symptoms vary from mild fever to ARDS complicating diagnosis, prognosis, 
and monitoring. Hence it is vital to ascertain a patient’s condition in a timely manner. 
Biomarkers are quantitative measurements used clinically for many conditions 
reflecting pathological development. A summary of the biomarkers discussed in this 
review can be found in Table 10.  
When assessing a patient with COVID-19 infection, biomarkers can be useful to 
clinicians in starting treatment and close monitoring. Though biomarkers may help 
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improve prognosis and outcomes, their significant variability between patients could 
affect the findings of the studies.  
Compared to other biomarkers, there is hesitancy in using WCC alone as it is 
influenced by many factors such as glucocorticoid treatment which increases it. 
Although WCC encompasses many cell types, NCs and LCs are most clinically 
relevant biomarkers. Multiple studies on COVID-19 have concurred high NLR in 
severe cases compared to non-severe cases due to high NC and low LC. The use of 
LC independently has been suggested as a potential biomarker of COVID-19 as 
patients have consistently low LC, with significant lymphopenia reported in critically 
ill patients(18). Therefore, further research on WCC accuracy for assessing disease 
progression is necessary. 
Although, most of the studies referenced in this review are single centred studies 
originating in Wuhan, China, the virus is now a global pandemic thus requiring 
international studies. As a copious amount of data was collected from the same 
location, it is possible patients may have been used in more than one study. 
Furthermore, categorising patients into severe and non-severe sub-groups is 
dependent on the definitions of severity of COVID-19. Two very different measures 
of severity used in some studies are ICU admission and onset of ARDS. This 
questions the heterogeneity across the studies and validity of the findings.  
Variability can be accounted to the differences in patient exposure to the virus or 
intraindividual variability, where differences in laboratory procedures lead to errors. 
Consequently, the sensitivity and specificity of biomarkers are useful indicators to the 
effectiveness, though not all studies discussed this. To ascertain the usefulness of 
the biomarkers listed in this review as indicators of disease progression, and whether 
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they definitively rise in COVID-19 requires further data collection. Statistical analysis 
using receiver-operator characteristic curves can also provide analysis sensitivity 
and false-positive rates.  
Findings of these studies has discovered changes in biomarker levels and may 
potentially be useful in creating a therapeutic intervention. For instance, one study 
has reviewed the use of anticoagulation therapy in patients with coagulopathy or 
marked rise in D-dimers in the setting of COVID-19(38). Low molecular weight 
heparin was found to be associated with better prognosis in severe cases. To further 
asses the role of anti-coagulants as a treatment, we encourage large interventional 
trails to study this.  
Many studies in this review were limited due to small sample size and selection bias 
if conducted at one centre. To improve reliability and reproducibility, more research 
into the prognostic value of biomarkers is necessary.  
 
Conclusion 
In conclusion, the work to date suggests that there is clear evidence of how the 
levels of biomarkers may change according to severity of COVID-19 infection. This 
can be used as an adjunct in clinical practice to guide treatment and admission to 
ICU. By doing so, it may improve prognosis and minimise the mortality rates. 
However, being in the infant stages of understanding the pathology of this infectious 
disease, we urge for further research worldwide to better understand the changes 
noted in this review. 
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Table 1 – Study Characteristics  
 
Author Study design Country Cohort size Biomarkers studied Comments 
Huang et al. 
(2020) (5) 
Prospective China 41 Lymphocytes, IL-6, D-
dimer, platelet count 
Compared to non-ICU patients, 
ICU patients had higher plasma 
levels of IL-6, D-dimer and 
platelets. Lymphopenia was 
more common in ICU patients 
than non-ICU patients 
Li et al. 2020 (39) Retrospective 
cohort; single 
centre  
 
China 132 CRP, WCC Critically severe patients had 
significantly higher CRP and 
WCC than severe or non-severe 
patients. 
Liu et al (9) Retrospective 
cohort; single 
centre  
 
China 140 CRP, IL-6 Significantly more patients in the 
severe group experienced higher 
CRP and IL-6 levels vs non-
severe. 
 
Ji et al. 2020 (10) Retrospective 
cohort; single 
centre  
China 33 CRP, D-dimer, LC The preprint study shows CRP, 
D-dimer significantly increased 
but LC decreased for patients in 
direct vs indirect contact to 
Wuhan – does not assess 
severity. CRP levels compared 
by ratio to other blood 
parameters indicated CRP 
changes prior to others.  
Tan et al. 2020 
(12) 
Retrospective 
cohort; single 
centre  
China 27 CRP, WCC ROC analysis showed strong 
association found between CRP 
levels and progression of 
disease. Interestingly, absolute  
values of increased WCC and 
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NLR found in influenza A or B 
group vs SARS-COV-2. 
Wang et al. 2020 
(40) 
Retrospective 
cohort; single 
centre  
China 27 CRP Greater CRP values correspond 
with the critical group, as groups 
were determined based on the 
diameter of largest lung lesion - 
CRP levels may indicate lung 
damage and development of 
disease. 
 
Qin et al. 2020 (8) 
 
Retrospective 
cohort; single 
centre  
China 452 CRP, IL-6 and LDH, WCC Significantly higher levels of 
CRP, IL-6, LDH and NC but low 
LC in severe COVID-19,vs non-
severe group. Surveillance may 
help in early screening of critical 
illness 
 
Wang et al. 2020 
(17) 
Retrospective 
cohort; single 
centre  
China  138 WCC, NC, LC, LDH, D-
dimer, blood urea, 
creatinine  
Higher WCC, specifically higher 
NC, lower LC and higher NLR in 
ICU vs non-ICU patients. Prior to 
the death of critical patients: NC, 
D-dimer, blood urea, and 
creatinine levels rose throughout 
until death, whilst the LC carried 
on falling. Elevated LDH also 
correlated with patients in ICU vs 
non-ICU. 
Chen N et al. 2020 
(15) 
 
Retrospective 
cohort; single 
centre 
China 99 WCC, NC, LC, LDH, CRP, 
platelet count, D-dimer, IL-
6, blood urea, serum 
creatinine 
Levels of LDH, CRP,D-dimer, IL-
6 increased over normal ranges 
in COVID-19- induced 
pneumonia patients, whereas 
increases and decreases were 
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seen in WCC (high NC, low LC), 
blood urea, serum creatinine and 
platelet count. Absolute LC 
values decreased across 
patients; destruction of T 
lymphocytes may lead to worse 
outcomes. 
Tan et al. 2020 
(18) 
Retrospective 
cohort; single 
centre  
China 90 WCC Graphical representation of time-
lymphocyte% model (TLYM%) 
using 5 randomly selected 
individuals to illustrate disease 
progression until death. TLYM % 
used for 90 hospitalised patients, 
it was able to categorise patients 
consistently. Surveillance may 
identify critically ill patients 
earlier. 
Gong et al. 2020 
(7) preprint 
 
Retrospective 
cohort; single 
centre 
 
China 100 WCC, CRP Preprint corresponds with other 
studies that a high WBC, NC and 
CRP suggests greater severity of 
disease. 
Luo et al. 2020 
(21) 
Retrospective 
cohort; single 
centre  
China 35 LDH Increased LDH levels are 
associated with patients in the 
severe group, indicating LDH 
may be reflective of severity of 
disease. 
Xiong et al. 2020 
(23) 
Retrospective 
cohort; single 
centre  
China 42 LDH Correlates LDH values with CT 
scores but no breakdown is 
present  
Mo P et al. 2020 
(24) 
Retrospective; 
single centre 
China 155 LDH, NC, CRP, platelet 
count 
LDH, NC, CRP and platelet 
count were higher in refractory 
vs general patients. Refractory 
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paitents had more cases of lung 
abnormalities, suggesting these 
biomarkers correlate with 
development of disease 
Ferrari D et al. 
(2020) (20) 
Retrospective; 
single centre 
Italy 141 LDH LDH measured in COVID-19 
positive vs negative patients and 
higher levels apparent in positive 
groups. 
 
Tang et al. 2020 
(26) 
Retrospective 
cohort; single 
centre  
China 183 D-dimer Abnormal coagulation results 
with markedly elevated D-dimer 
are common in deaths with 
COVID-19 
Zhou et al. 2020 
(32) 
Retrospective 
cohort; multi-
centre 
China 191 D-dimer, hs-TnI, platelet 
count 
D-dimer levels greater than 
1μg/mL can help clinicians in 
identifying patients with poor 
prognosis at earlier stage 
There were significantly higher 
levels of platelets and hs-TnI in 
non-survivors compared to 
survivors 
Guan et al. 2020 
(22) 
 
Retrospective 
cohort; single 
centre  
China 1099 D-dimer, Platelet count, 
CRP lymphocytes and LDH 
Although there were evident 
differences in lymphocytes 
(lymphocytopenia), platelet count 
(rose) and D-dimer (rose) in 
patients who experienced 
composite endpoints (ICU 
admission, invasive mechanical 
ventilation and death) there was 
no statistical analysis performed 
 
LDH measured in 675. Higher 
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LDH levels present in majority of 
severe patients vs non-severe. 
 
Liu et al. 2020 (41) Retrospective 
cohort; single 
centre  
China  12 Lymphocytes, Albumin, 
Neutrophils, CRP, 
PaO2/FiO2, platelet count, 
creatinine and LDH 
Ct value of virus correlated 
strongly with CRP, albumin and 
LDH among others.  
Murray score for ARDS 
correlated with the same 
markers.  
Liu et al. 2020 (42) Retrospective 
cohort; single 
centre  
China  78 CRP, Albumin, Platelet 
count, D-dimer, AST, ALT, 
Creatinine 
Increased CRP and decreased 
albumin strongly correlated with 
disease progression 
Ruan et al. 2020 
(43) 
Retrospective 
cohort; single 
centre  
China  150 WBC counts, lymphocytes, 
platelets, albumin, total 
bilirubin, urea, creatinine, 
myoglobin, cardiac 
troponin, CRP and IL-6 
 
Cardiac troponin, Myoglobin, 
CRP and IL-6 significantly 
increased in cases with mortality 
Yang et al. 2020 
(44) 
Retrospective 
cohort; single 
centre  
China 52 Haemoglobin, 
lymphocytes, Platelet 
count, prothrombin time, 
bilirubin, creatinine and 
lactate. 
Higher levels of platelets in 
severe group but 
lymphocytopenia seen as the 
most common marker of 
infection. 
Young et al. 2020 
(45) 
Descriptive Singapore 18 Haemoglobin, 
lymphocytes, platelet 
count, neutrophils, CRP 
and LDH 
Lower platelets found in severe 
group, but statistical analysis 
was not performed 
Liu et al. 2020 (30) Retrospective 
cohort; single 
centre  
China  383 Platelet parameters: 
platelet count, volume, 
distribution width and larger 
cell ratio 
Thrombocytopenia associated 
with mortality 
Patients split on basis of 
thrombocytopenia not severity  
Yang et al 2020 Retrospective China 1476 Platelet count Lowest platelet count associated 
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(31) cohort; single 
centre  
with mortality 
 
Shi et al 2020 (33) Retrospective 
cohort; single 
centre  
China 416 Cardiac troponin, platelet 
count, creatinine kinase 
Greater proportion of cardiac 
injury, marked as a rise in 
creatinine kinase and cardiac 
troponin, is more likely to require 
non-invasive/invasive ventilation 
compared to those without  
Xiang et al. 2020 
(35) 
Retrospective 
cohort; single 
centre  
China 28 AST, GGT, ALP, albumin, 
creatinine kinase, CKMB, 
CRP, creatinine, urea and 
cystatin C 
Serum values of urea, creatinine 
and cystatin-C significantly 
increased in severe COVID-19.  
 
Cheng et al.  2020 
(36) 
Prospective 
cohort; single 
centre 
China 701 Creatinine Raised creatinine levels 
associated with poor outcome in 
COVID infection  
 
Zhou et al. 2020 
(37) 
Retrospective 
cohort; single 
centre  
 
China 178 Urinalysis: proteinuria, 
haematuria, leucocyturia  
 
Urinalysis on admission can 
effectively highlight kidney 
impairment 
Chen L et al 
(2020) (46) 
Prospective 
cohort; single 
centre 
China 29 IL-6 Increased expression of IL-2R 
and IL-6 in serum is expected to 
predict the severity of COVID-19 
Liu et al. (2020) 
(47) 
Retrospective 
cohort; single 
centre 
China 80 IL-6, CRP, LDH, ferritin and 
D-dimer 
Baseline IL-6, CRP, LDH and 
ferritin was closely related to 
severity of COVID-19. 
 
Elevated IL-6 was significantly 
related to clinical manifestations 
of severe type patients 
Diao et al (2020) 
(48) 
Retrospective 
cohort; multi-
China 552 COVID; 
40 healthy 
T-cells, IL-6 T cells are reduced significantly 
and negatively correlated to IL-6 
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IL-6 = interleukin-6; ICU = intensive care unit; CRP = C-reactive protein; WCC = white cell count; LC = leucocyte count; 
ROC = Receiver operating characteristic; NLR = neutrophil:lymphocyte ratio; NC = neutrophil count; LDH = lactate 
dehydrogenase; hs-TnI = high sensitivity troponin I; AST = aspartate aminotransferase; ALT = alanine aminotransferase; 
GGT = gamma-glutamyl transpeptidase; ALP = alkaline phosphatase; CKMB = creatine kinase myocardial band 
 
 
 
 
 
centre in COVID-19  
Wu et al (2020) 
(49) 
Retrospective 
cohort; multi-
centre 
China 150 IL-6, D-dimer, LDH, 
neutrophil count 
ARDS development in COVID-
19 is significantly correlated with 
rise in IL-6, D-dimer, LDH and 
neutrophil count   
Zhang et al  
(2020) (50) 
Retrospective; 
single centre 
China 343 D-dimer D-dimer on admission of greater 
than 2.0 µg/mL could effectively 
predict in-hospital mortality in 
patients with COVID-19 and 
could be an early and helpful 
marker to improve management 
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Table 2: Studies that compare C-reactive protein for COVID-19 
Author Level in non-
severe patient 
Level in severe patient Confidence interval 
(CI) range and p value 
Comments 
Li H, et al. 2020 
(39) 
33.22 ±32.21 
 
66.04 ±44.89  
 
97.44 ±58.60  
(critically severe) 
P = 0.001 for all Critically severe patients had 
significantly higher CRP than 
severe or non-severe patients. 
SAA correlated with CRP too 
consistently, indicating both 
should be used to reflect 
severity of disease – but study 
lacks a control group. 
Liu F, et al (9) >8.0 = 56.1% of 
patients 
0–8.0 = 43.9% of 
patients 
>8.0 = 93.9% of patients  
0–8.0 = 6.1% of patients 
P < 0.001 for all Significantly more patients in 
the severe group experienced 
higher CRP levels vs non-
severe.  
Qin et al. 2020 
(8) 
33.2 (8.2–59.7)  57.9 (20.9–103.2)  P < 0.001 Higher levels of CRP recorded 
in the severe group vs non-
severe group is suggestive that 
CRP can be monitored to 
assess progression of disease. 
Ji et al. 2020 (10) 11.89 (9.74-
23.36) 
 
(Indirect contact) 
5.68 (2.80-13.0) 
 
(Direct contact) 
N/A Stratifies patients by direct and 
indirect contact to Wuhan – 
does not assess severity  
Tan et al. 2020 
(12) 
N/A N/A CRP (R = .62; P < .01) 
ROC= 0.87 (95% CI 
0.10–1.00)  
Cut‐ off= 20.42 mg/L 
Sensitivity=83%  
Specificity=91% 
Absolute values not reported – 
instead performs ROC 
analysis, showing significant 
increase in CRP levels prior to 
changes in CT scores for early 
periods of severe group.  
Wang et al. 2020 1.52 ± 1.56 (mild) 54.15 ± 1.06 (severe)  Mild: moderate  Groups were determined 
Journal Pre-proof
Jou
rna
l Pr
e-p
roo
f
 25 
(40) 16.76 ± 18.38  
(moderate) 
105.00 ± 12.73 
(critical) 
 
P = 0.007 
Moderate: severe 
P = 0.511 
Severe: critical 
P = 0.947 
based on the diameter of 
largest lung lesion. Greater 
CRP values are more 
prominent in critical group – 
indicating lung damage.  
 
CRP = C-reactive protein; ROC = Receiver operating characteristic 
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Table 3: Studies that compare IL-6 for COVID-19 
IL-6 = interleukin-6; ARDS = Acute Respiratory Distress Syndrome; ICU = intensive care unit 
 
 
Author Level in non-
severe patient 
Level in severe 
patient 
Confidence interval (CI) range 
and p value 
Comments 
Chen et al (2020) 
(46) 
34 +/- 7 72 +/- 12 P < 0.0001 Increased expression of IL-2R 
and IL-6 in serum is expected 
to predict the severity of 
COVID-19 
23. Liu et al. (2020) 
(47) 
2.4 (2.1-2.9) 36.5 (30.8-42) P < 0.0001 Severity of COVID-19 could be 
predicted with baseline IL-6 
levels  
Diao et al (2020) (48) 51 +/- 74 186 +/- 283 P < 0.0001 Significantly higher baseline 
levels of IL-6 in those requiring 
ICU compared to those who do 
not 
Huang et al (2020) 
(5) 
5 (0-11.2) 6.1 (1.8-37.7) P < 0.0001 Significantly higher baseline 
levels of IL-6 in those requiring 
ICU compared to those who do 
not 
Qin et al (2020) (8) 13.3 (3.9-41.1) 25.5 (9.5-54.5) P < 0.0001 Significantly higher levels of IL-
6 in sever and critical COVID-
19. Surveillance may help in 
early screening of critical 
illness 
Wu et al (2020) (49) 6.3 (5.4-7.8) 7.4 (5.6-10.9) P < 0.0001 ARDS development in COVID-
19 is related to rise in IL-6 
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Table 4: Studies that compare WCC for COVID-19 
 
 
Author Level in non-severe 
patient (x109/L) 
Level in severe patient 
(x109/L) 
Confidence interval 
(CI) range and p value 
Comments 
Qin et al. 2020 (8) WCC= 4.9 (3.7–6.1)  
NC = 3.2 (2.1–4.4)  
LC = 1.0 (0.7-1.3) 
NLR = 3.2 (1.8–4.9)  
 
WCC= 5.6 (4.3–8.4)  
NC = 4.3 (2.9–7.0) 
LC = 0.8 (0.6-1.1) 
NLR = 5.5 (3.3–10.0)  
 
P < 0.001 for all 
 
 
Retrospective + China + 452 
Significantly higher NLR in severe 
patients. Monitoring may aid in 
early screening of critical illness. 
Wang et al. 2020 (17) WCC = 4.3 (3.3-5.4) 
NC = 2.7 (1.9-3.9) 
LC = 0.9 (0.6-1.2) 
(non-ICU) 
WCC = 6.6 (3.6-9.8) 
NC = 4.6 (2.6-7.9) 
LC = 0.8 (0.6-1.1) 
(ICU) 
P = 0.003 
P < 0.001 
P = 0.03 
Retrospective + China + 138 
Non-ICU vs ICU patients had 
drastically lower WCC, checking 
low LC and high NC may help in 
early detection of disease 
progression. 
Chen N et al. 2020 (15) WCC = 7.5 (3.5-9.5 normal range) 
NC = 5.0 (3.3-8.1 normal range) 38% increase  
LC = 0.9 (1.1-3.2 normal range) 35% decrease 
 
N/A Absolute values of 99 patients 
obtained in patients with 
pneumonia. Surveillance of 
NC/LC may reflect severity of 
lung abnormalities. 
Tan et al. 2020 (18) N/A P < 0.001 Only lymphocyte % (LYM%) 
representation is graphical .TLYM 
% used for 90 hospitalised 
patients, it was able to categorise 
patients consistently. Surveillance 
may identify critically ill patients 
earlier. 
Gong et al. 2020 (7) 
preprint 
WBC >9.5 x 109/L 
NC > 7.305 x 109/L 
R=-0.54, P<0.001 
R=-0.585, P<0.001 
The preprint suggests high WBC 
and NC indicates the higher the 
likelihood the severity of disease 
will progress to a critical stage 
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WCC = White cell count; NC = neutrophils; LC = lymphocytes; WBC = white blood cell 
Table 5: Studies that compare LDH for COVID-19 
 
 
LDH = lactate dehydrogenase; ICU = intensive care unit 
 
 
Author Level in non-
severe patient 
(U/L) 
Level in severe 
patient (U/L) 
Confidence interval (CI) 
range and p value 
Comments 
Luo et al. 2020 (21)   151 (139–180) 
 
248 (162–273) 
 
P <  0.002 
 
Higher LDH levels reported 
in severe patient's vs non 
severe.  
Xiong et al. 2020 (23) N/A N/A R = 0.78, P < 0.001 for 
correlation between LDH 
and CT score 
LDH values linked to CT 
scores (used to assess 
severity)-no absolute values 
Guan et al. 2020 (22) ≥250 (205/551) 
37.2% of patients 
≥250 (72/144) 
58.1% of patients 
N/A Multi-centre + China + 1099 
Higher LDH levels present in 
majority of severe patients 
vs non-severe. LDH 
measured in 675. 
Mo P et al. 2020 (24) 241 (198- 338) 
(General) 
293 (193-434) 
(Refractory) 
P = 0.017 Retrospective + China + 
155, refractory vs general  
Ferrari D et al. 2020 (20) 276.4±118.3  
(COVID-19 
negative) 
388.0±154.5  
(COVID-19 
positive) 
P <0.001 Retrospective + Italy + 141 
LDH measured, COVID-19 
positive vs negative 
Wang et al. 2020 (17) 212 (171-291) 
(non-ICU) 
435 (302-596) 
(ICU) 
P < 0.001 Retrospective, single-centre 
+ China + 138, non-ICU vs 
ICU 
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Table 6: Studies that compare D-dimer for COVID-19 
 
ICU = intensive care unit 
Author Level in non-
severe patient 
Level in severe 
patient 
Confidence interval (CI) range 
and p value 
Comments 
Tang et al. 
(2020)(26) 
0.61 (0.35-1.29) 2.12 (0.77-5.27) N/A Abnormal coagulation results 
with markedly elevated D-
dimer are common in deaths 
with COVID-19 
Zhou et al. (2020) 
(32) 
0.6 (0.3-1.0) 5.2 (1.5-21.1) P < 0.001 D-dimer levels greater than 
1μg/mL can help clinicians in 
identifying patients with poor 
prognosis at earlier stage 
 
Guan et al. (2020) 
(22) 
43.2% with > 0.5 
mg/L 
59.6% with > 0.5 
mg/L 
N/A D-dimer levels much higher in 
those requiring ICU admission 
and invasive ventilation 
however statistical analysis not 
performed 
Huang et al. 
(2020)(5) 
0.5mg/L 2.4mg/L P = 0.0042 Compared to non-ICU patients, 
ICU patients had significantly 
higher levels of D-dimer 
Zhang et al  
(2020) (50) 
0.41 mg/L (0.15 
– 0.69) 
4.76 mg/L (2.99-
11.9) 
P < 0.001 D-dimer on admission of 
greater than 2.0 µg/mL could 
effectively predict in-hospital 
mortality in patients with 
COVID-19 and could be an 
early and helpful marker to 
improve management 
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Table 7: Studies that compare platelet count for COVID-19 
Author Level in non-
severe patient 
Level in severe 
patient 
Confidence interval (CI) range 
and p value 
Comments 
Guan et al. 2020 (22) 172,000 137,500 N/A Although there were evident 
differences in lymphocytes 
(lymphocytopenia), platelet 
count (rose) and D-dimer 
(rose) in patients who 
experienced composite 
endpoints (ICU admission, 
invasive mechanical ventilation 
and death) there was no 
statistical analysis performed 
Huang et al. 2020(5) 149,000 196,000 P = 0.45 Compared to non-ICU patients, 
ICU patients had higher 
plasma levels of IL-6, D-dimer 
and platelets. But this 
difference was not significant.  
Liu et al. 2020 (41) 173,200 ± 55.37  143,900 ± 64.81 P = 0.116 Ct value of virus correlated 
strongly with CRP, albumin 
and LDH among others.  
Murray score for ARDS 
correlated with the same 
markers.  
Liu et al. 2020 (42) 186,200  
 
139,500  
 
N/A Increased CRP and decreased 
albumin strongly correlated 
with disease progression 
Ruan et al. 2020 (43) 221,000 
(78,000) 
 
173,600 (67,000) 
 
P < 0.001 Cardiac troponin, Myoglobin, 
CRP and IL-6 significantly 
increased in cases with 
mortality 
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Wang et al. 2020 (17) 165,000  
 
142,000 
 
P < 0.78 Higher WCC, specifically 
higher NC, lower LC and 
higher NLR in ICU vs non-ICU 
patients. Prior to the death of 
critical patients: NC, D-dimer, 
blood urea, and creatinine 
levels rose throughout until 
death, whilst the LC carried on 
falling. Elevated LDH also 
correlated with patients in ICU 
vs non-ICU. 
Yang et al. 2020 (44) 191,000 
(63,000) 
 
164,000 (74,000) 
 
N/A  
 
Higher levels of platelets in 
severe group but 
lymphocytopenia seen as most 
common marker of infection 
Mortality used to indicate 
severity 
Young et al. 2020 
(45) 
159,000 
 
156,000 
 
N/A Lower platelets found in severe 
group, but statistical analysis 
was not performed.  
Severity determined by 
supplemental oxygen 
requirement 
Zhou et al. 2020 (32) 220,000  
 
165,500  
 
P < 0·0001 
 
D-dimer levels greater than 
1μg/mL can help clinicians in 
identifying patients with poor 
prognosis at earlier stage 
There were significantly higher 
levels of platelets and hs-TnI in 
non-survivors compared to 
survivors 
Mortality used to determine 
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severity  
41. Liu et al. 2020 
(30) 
186,000  
(160,000–
227,000)  
 
105,000 
(92,000–
116,000)  
 
P < 0.001 Thrombocytopenia associated 
with mortality 
Patients split on basis of 
thrombocytopenia not severity 
 
42. Yang et al. 2020 
(31) 
203,000 
(155,000 – 
257,000) 
79,000 (43,000 – 
129,000) 
P < 0.001  
 
Lowest platelet count 
associated with mortality 
Mortality used to indicate 
severity 
Uses nadir platelet count  
 
IL-6 = interleukin-6; ICU = intensive care unit 
 
 
 
 
 
 
 
 
 
 
Table 8: Studies that compare Cardiac Troponin Levels for COVID-19 
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Hs-TnI = high sensitivity troponin I 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Studies that compare creatinine levels for COVID-19 
Author Level in non-
severe patient 
Level in severe 
patient 
Confidence interval (CI) range 
and p value 
Comments 
Zhou et al. (2020) 
(32) 
3.0 (1.1-5.5) 22.2 (5.6 – 83.1) P < 0.0001 Significantly higher levels of 
hs-TnI in non-survivors 
compared to survivors 
Shi et al. (2020)(33) <0.006 ug/L 
(<0.006-0.009) 
0.19 ug/L (0.08-
1.12) 
P < 0.0001 Significantly higher levels of 
hs-TnI in patients who require 
mechanical ventilation 
compared to those who do not 
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Table 10: Summary of Changes in Biomarkers Seen in Severe COVID-19 Infection 
Author Level in non-
severe patient 
Level in severe 
patient 
Confidence interval (CI) range 
and p value 
Comments 
45. Xiang et al. 2020 
(35) 
N/A N/A P < 0.001 Serum values of urea, creatine 
and cystatin-C significantly 
increase in severe COVID-19 
No values provided – only 
graphical depiction of results 
46. Cheng et al. 2020 
(36) 
77 ± 31 
 
132 ± 39 
 
P < 0.001  
 
Raised creatinine levels 
associated with poor outcome 
in COVID infection 
Patients split on basis of 
creatine level not severity 
 
47. Zhou et al. 2020 
(37) 
65.3 (56.5-74.3)  
 
71.0 (55.8-89.4)  
 
P = 0.067 Urinalysis on admission can 
effectively highlight kidney 
impairment 
Patients split on basis of 
abnormal urinalysis  
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CRP = C-reactive protein; SAA = serum amyloid A; IL-6 = interleukin 6; LDH = lactate dehydrogenase; WCC = White cell 
count
Biomarker Change in severe COVID-19 infection 
CRP Increase 
SAA Increase 
IL-6 Increase 
LDH Increase 
WCC NLR increases 
LC decrease 
D-dimer Increase 
Platelet count Decrease 
Cardiac troponin Increase 
Renal biomarkers Urea & creatinine increase 
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Figure 1: PRISMA Flow Diagram 
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Highlights 
 There are many biomarkers with suggested roles in monitoring COVID-19 
infection 
 Increases in CRP and D-dimers have strong associations with mortality  
 Likewise, decreases in platelet count strongly associated with mortality  
 Ultimately more research is needed to determine prognostic benefit 
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